Being the third¹ liquid biopsy test for Biocartis, the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
The Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
A revolution in liquid biopsy cancer research.
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study  by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Press Release: Mechelen, Belgium, 27 June 2018
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).